Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.

Clin Pharmacokinet · 2018 · PMC5856878 · PMID 28853050

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

12.5 months; HR 0.92, 95% CI 0.78–1.10, p = 0.366), a positive trend was observed.

also in 11,005 other papers

showed a trendno p-value reported

also showed a trend toward improved OS in patients who were WT RAS and BRAF in the FOLFIRI plus panitumumab arm compared with the FOLFIRI plus bevacizumab arm [ 46 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.